ArticleCureus2026

First-Line Enfortumab Vedotin Plus Pembrolizumab in Platinum-Ineligible Urothelial Carcinoma: A Three-Case Series.

Daisuke Igarashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.